Thursday, December 3, 2020
Home Latest Pharma-News Initiation Of First Large-Scale Registry :To Evaluate Real-World Lipid Management And The...

Initiation Of First Large-Scale Registry :To Evaluate Real-World Lipid Management And The Effectiveness Of PCSK9 Inhibitors

Nov. 15, 2019: Amgen and the Duke Clinical Research Institute (DCRI) announced plans to initiate the Cardiovascular Multi-dimensional Observational Investigation of the Use of PCSK9 inhibitors (cvMOBIUS) study in order to calculate lipid management and the impact of PCSK9 inhibitors on cardiovascular (CV) outcomes.

The  study performed  across the U.S. and Canada and will start patient enrollment by this month.”The clinical evidence assisting  the efficacy and safety of PCSK9 inhibitors including Repatha® (evolocumab) in patients with cardiovascular disease is well established, but still there is lot to learn about the benefits of these medicines in the real world.”

- Advertisement -

One of the  most important modifiable risk factors for cardiovascular diseaseis “LDL-C, so lipid management is an vital element in reducing future CV events and improving clinical outcomes for high-risk patients.”


Please enter your comment!
Please enter your name here

sixteen + fourteen =

Most Popular

FDA approves Xolair® (omalizumab) for adults with nasal polyps

December 01, 2020: "Roche announced that the U.S. Food and Drug Administration (FDA) has approved the company’s supplemental Biologics License Application (sBLA)...

UK authorises Pfizer/BioNTech COVID-19 vaccine

December 02, 2020: "A Department of Health and Social Care spokesperson said: The government has accepted the recommendation from...

WHO Releases COVID-19 App for Trusted and Timely Updates

 December 01, 2020: The WHO has published a new mobile app to centralize the most trusted updates about COVID-19, and to guide...